HIRO-CAPITAL
7.2.2020 01:03:10 CET | Business Wire | Press release
Fresh from a legendary launch at CES 2020, NURVV – the biomechanics innovator using British science to disrupt the global wearables industry – is today announcing it has closed its first venture funding round, led by Hiro Capital.
Hiro Capital – the new Sports technology, Games and Esports VC Fund led by Inspired Entertainment co-founder Luke Alvarez, Games Workshop co-founder Ian Livingstone CBE and Cherry Freeman, co-founder of LoveCrafts - has invested $9m in NURVV’s husband and wife team of serial entrepreneurs Jason and Ulrica Roberts.
The money will be used to bring NURVV’s debut product, NURVV Run, to a global market; to fund further research and development into its patented biomechanics sensor technologies and to support the founders in achieving their aim of helping 10 million runners to improve their technique.
NURVV Run was unveiled at this year’s Pepcom during the Consumer Electronics Show in Las Vegas to great acclaim, featuring on multiple Best of CES lists from the likes of Wired, CNET and Gear Patrol. NURVV Run also won US Today’s Editor’s Choice award which handpicks winners that strike a balance in innovation, technology, design, and value.
Tested by hundreds of athletes, universities and leading institutions including SATRA Technology and the National Physical Laboratory over the past three years, the system uses 32 high-precision sensors fitted inside lightweight insoles to accurately capture data from the feet at 1,000 times per second, per sensor.
This data, which includes unique running metrics such as cadence, step length, footstrike, pronation and balance, is fed into the NURVV Run coaching app to show a complete picture of the wearer’s running technique. It uses advanced biomechanics to deliver simple, actionable insights as well as personalised coaching that gives guidance on how to improve before, during and after each run.
Its in-run, real-time coaching creates gamified speed and technique workouts to help wearers run at a target pace, to a chosen finish time or beat a personal record with responsive audio, visual and haptic feedback. Real-time prompts detailing step length, cadence and pace on critical splits also help keep runners on track to hit their goals.
This not only helps runners improve their technique and pace, it can help reduce injury via a Running Health score.
The Running Health score helps reduce injury by analysing each runner’s training load, pronation, cadence and balance – to identify problem areas before they become serious. Runners can also optimise their training with recommendations on the right distance to run to achieve their optimal training zone and avoid overtraining.
The NURVV Run insoles are compatible with all running shoes, are rain and mud proof and come with a five-hour active battery life. The system ships with two GPS trackers and access to the free NURVV Run Coaching app. Runners can connect the system to IOS, Apple Watch, Android and to ANT+ (Garmin) wearables.
“Runners are already able to collect a huge amount of data about each and every run they do. However, most of what they capture is historic, inaccurate and provides few insights on how to be a better runner,” said Jason Roberts, founder and CEO of NURVV. “NURVV Run revolutionises how people run by accurately capturing the metrics that matter most, directly from the point of action at the foot, before using live coaching to help them improve in a simple, easy-to-understand way.”
“From the very beginning of this journey we kept coming back to the same question: ‘Why is running measured from the wrist, when most of the important metrics happen at the feet?’,” added co-founder Ulrica Roberts. “Driven by the idea we could revolutionise running by putting core biomechanical principles at the heart of our solution, we sought out the expertise to make it happen.”
“Combining our cutting-edge wearable technology, in-house biomechanics expertise, and ongoing dialogue with the running community, NURVV Run is the most comprehensive tool for runners who crave more detailed information on their performance and technique,” said Dr. Grant Trewartha, head of biomechanics at NURVV.
Luke Alvarez, Managing Partner of Hiro, said: “Hiro is delighted to be investing in NURVV as our Fund’s fourth deal and our first Sports tech investment. NURVV’s success comes from putting the athlete’s body at the heart of everything they do. NURVV is based on fundamental patented sensor technologies combined with deep biomechanics and data science that have revolutionary potential across sports, gaming, VR/AR and wellness. Jason and Ulrica are extraordinary entrepreneurs and we are excited to be working with them and their team to take NURVV to the next level.”
NURVV Run has been tested during 22 million steps of durability testing and 30,000 miles covered on the road.
ENDS
About NURVV
NURVV is on a mission to provide runners with the power to understand what their bodies are truly capable of and find their true potential. We pioneer the latest advances in technology and biomechanics. We capture running from the point of action and analyze run-data using advanced biomechanics to deliver actionable insights and live in-run coaching. We are dedicated to all runners who want to improve their running and aim to change 10 million lives with a new way of knowing by 2025. https://www.nurvv.com/
About Hiro Capital
Hiro Capital is a Luxembourg / London technology Venture Capital fund which invests in European and UK innovators in Games, Esports and Digital Sports. Hiro Capital generally invests at the post-seed Series A and B stages. We invest both in front-end Content creators in Games, Esports and Digital Sports and in deep tech sector-specific applications of Cloud, Mobile, Streaming, Big Data, AI, Wearables, AR and VR technologies.
We back experienced entrepreneurial teams, building innovative technologies and content with a strongly differentiated proposition and with the scaling opportunity to become very large.
We are Games, Esports and Sports investors who are also Games, Esports and Sports entrepreneurs. Our core belief is that Games, Esports and Digital Sports will be a central pillar of Entertainment, Economic and Social Life in the mid 21st century. We invest in the innovators who are building that future. https://hiro.capital/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005997/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
